Skip to main content

Advertisement

SpringerLink
Log in

Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial

  • ASSISTED REPRODUCTION TECHNOLOGIES
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose

To compare the efficacy of cabergoline (Cb2) and intravenous human albumin (HA) in the prevention of ovarian hyperstimulation syndrome.

Methods

In this randomized controlled trial study, 138 women who were at high risk for developing OHSS were randomly allocated into two groups. In Group one, 20 gr of HA 20% was infused over 1 h. Group two received 0.5 mg per day of Cb2 orally for 7 days, starting on oocyte pickup day. All patients were visited seven and 14 days after oocyte retrieval to determine early clinical or ultrasound evidence of OHSS.

Results

Moderate OHSS was observed in 33 versus 14 cases in the HA and Cb2 groups, respectively, which was significantly different. The number of severe OHSS cases in the HA group was significantly higher than in the Cb2 group (P < 0.001).

Conclusions

Prophylactic oral low dose cabergoline was more effective and less costly than intravenous human albumin in the prevention of OHSS in high-risk patients. (NCT01009567)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mathur R, Kailasam CH, Jenkins J. Review of the evidence base of strategies to prevent ovarian hyper stimulation syndrome. Hum Fertil. 2007;10(2):75–85.

    Article  CAS  Google Scholar 

  2. Shoham Z, Weissman A, Barasch A, Borenstein R, Schachter M, Insler V. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertil Steril. 1994;62:137–42.

    PubMed  CAS  Google Scholar 

  3. Isik AZ, Gokmen O, Zeyneloglu HB, Kara S, Keles G, Gulekli B. Intravenous albumin prevents moderate-severe ovarian hyperstimulation in-vitro fertilization patients: a prospective randomized and controlled study. Eur J Obstet Gynecol Reprod Biol. 1996;70:179–83.

    Article  PubMed  CAS  Google Scholar 

  4. Gokmen O, Ugur M, Ekin M, Keles G, Turan C, Oral H. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme:a prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol. 2001;96:187–92.

    Article  PubMed  CAS  Google Scholar 

  5. Ben-Chetrit A, Eldar-Geva Y, Gal M, Huerta M, Mimon T, Algur N, Diamant YZ, Margalioth EJ. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod. 2001;16:1880–4.

    Article  PubMed  CAS  Google Scholar 

  6. Isikoglu M, Berkkanoglu M, Senturk Z, Ozgur K. Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study. Fertil Steril. 2007;88(4):982–5.

    Article  PubMed  Google Scholar 

  7. Costabile L, Unfer V, Manna C, Gerli S, Rossetti D, Di Renzo GC. Use of intramuscular progesterone versus intravenous albumin for the prevention of ovarian hyperstimulation syndrome. Gynecol Obstet Invest. 2000;50:182–5.

    Article  PubMed  CAS  Google Scholar 

  8. Bellver J, Muñoz EA, Ballesteros A, Soares SR, Bosch E, Simón C, Pellicer A, Remohí J. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Human Reprod. 2003;18(11):2283–8.

    Article  CAS  Google Scholar 

  9. Chen CD, Chao KH, Yang JH, Chen SU, Ho HN, Yang YS. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2003;80(1):86–90.

    Article  PubMed  Google Scholar 

  10. Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Papadimas I, Tarlatzis BC. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(1):188–96.

    Article  PubMed  CAS  Google Scholar 

  11. Gómez R, Soares SR, Busso C, Garcia-Velasco JA, Simón C, Pellicer A. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med. 2010;28(6):448–57.

    Article  PubMed  Google Scholar 

  12. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2 dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006;147(11):5400–11.

    Article  PubMed  CAS  Google Scholar 

  13. Saylan A, Arioz DT, Koken T, Dilek H, Saylan F, Yilmazer M. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand. 2010;89(5):292–9.

    Article  Google Scholar 

  14. Alvarez C, Alonso-Muriel I, García G, Crespo J, Bellver J, Simón C, Pellicer A. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod. 2007;22(12):3210–4.

    Article  PubMed  CAS  Google Scholar 

  15. Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT, Jine LT, Nagy P, Abdelmassih R. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod BioMed Online. 2008;17(6):751–5.

    Article  PubMed  CAS  Google Scholar 

  16. Sohrabvand F, Ansaripour S, Bagheri M, Shariat M, Jafarabadi M. Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. Int J Fertil Steril. 2009;3(1):35–40.

    Google Scholar 

  17. Soliman BS. Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome. Middle East Fertil Soc J. 2011;16:56–60.

    Article  Google Scholar 

  18. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430–40.

    Article  PubMed  CAS  Google Scholar 

  19. Hwang JL, Lin YH, Soew KM. Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels. Int J Gynaecol Obstet. 2010;108(2):159–60.

    Article  PubMed  CAS  Google Scholar 

  20. Youssef MA, van Wely M, Hassan MA. Review Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update. 2010;16(5):459–66.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Number 12, East Hafez Avenue, Bani Hashem Street, Resalat Highway, Tehran, Iran, P.O. Box: (16656-59911)

    Ensieh Shahrokh Tehraninejad, Maryam Hafezi, Arezoo Arabipoor & Akram Bahmanabadi

  2. Faculty of Medicine, Tehran University of Medical Science, Tehran, Iran

    Ensieh Shahrokh Tehraninejad & Elham Aziminekoo

  3. Department of Epidemiology and Reproductive Health, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran

    Mohammad Chehrazi

Authors
  1. Ensieh Shahrokh Tehraninejad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maryam Hafezi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arezoo Arabipoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elham Aziminekoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammad Chehrazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akram Bahmanabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ensieh Shahrokh Tehraninejad.

Additional information

Capsule In the following report, we found that the oral cabergoline tablet (dostinex) is more effective and less costly than intravenous human albumin in the prevention of Ovarian Hyperstimulation Syndrome.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 34 kb)

ESM 2

(DOC 217 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tehraninejad, E.S., Hafezi, M., Arabipoor, A. et al. Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. J Assist Reprod Genet 29, 259–264 (2012). https://doi.org/10.1007/s10815-011-9708-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-011-9708-4

Keywords

Search

Navigation